Payment overview · 2025
General Payments
$165.85
9 reported records · 8 companies
Healthcare provider profile · identity verified
Jerry Wayne Lawson, MD
Allopathic & Osteopathic Physicians|Family Medicine · JAMESTOWN, KY · NPI 1326046913
Verified facts
What the public records show
CMS Open Payments records show Jerry Wayne Lawson, MD received $165.85 in general payments during 2025 across 9 reported records.
Lilly USA, LLC accounted for 19.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Mounjaro by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $31.97 | 19.3% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $25.33 | 15.3% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $21.89 | 13.2% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $19.22 | 11.6% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $18.02 | 10.9% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $17.44 | 10.5% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $16.96 | 10.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.02 | 9.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $165.85 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $31.97 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $25.33 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $21.89 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $19.22 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $18.02 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $17.44 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16.96 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $15.02 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 54 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
54 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Omeprazole | Omeprazole | 294 | 46 |
| Levothyroxine Sodium | Levothyroxine Sodium | 262 | 44 |
| Lisinopril | Lisinopril | 250 | 49 |
| Metformin Hcl | Metformin Hcl | 246 | 48 |
| Atorvastatin Calcium | Atorvastatin Calcium | 241 | 48 |
| Gabapentin | Gabapentin | 214 | 31 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 192 | 39 |
| Amlodipine Besylate | Amlodipine Besylate | 188 | 34 |
| Meloxicam | Meloxicam | 187 | 47 |
| Quetiapine Fumarate | Quetiapine Fumarate | 174 | 22 |
| Diclofenac Sodium | Diclofenac Sodium | 142 | 22 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 142 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 137 | 24 |
| Pantoprazole Sodium | Pantoprazole Sodium | 133 | 31 |
| Furosemide | Furosemide | 125 | 22 |
| Metoprolol Succinate | Metoprolol Succinate | 121 | 23 |
| Montelukast Sodium | Montelukast Sodium | 115 | 16 |
| Eliquis | Apixaban | 110 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 109 | 26 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 106 | 13 |
| Xarelto | Rivaroxaban | 106 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 97 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 97 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 94 | 12 |
| Losartan Potassium | Losartan Potassium | 92 | 19 |
| Sertraline Hcl | Sertraline Hcl | 88 | 16 |
| Simvastatin | Simvastatin | 87 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 86 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 85 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 83 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 79 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 78 | 17 |
| Atenolol | Atenolol | 76 | 12 |
| Carvedilol | Carvedilol | 76 | 16 |
| Ibuprofen | Ibuprofen | 71 | 11 |
| Glimepiride | Glimepiride | 66 | 16 |
| Ventolin Hfa | Albuterol Sulfate | 65 | 14 |
| Finasteride | Finasteride | 62 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 61 | suppressed |
| Januvia | Sitagliptin Phosphate | 61 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 58 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 56 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 56 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 54 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 53 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 52 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 51 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 49 | suppressed |
| Amoxicillin | Amoxicillin | 48 | 36 |
| Mirtazapine | Mirtazapine | 48 | 11 |
| Baclofen | Baclofen | 45 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 45 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 44 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 44 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 43 | suppressed |
| Ezetimibe | Ezetimibe | 42 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 41 | 11 |
| Linzess | Linaclotide | 41 | suppressed |
| Potassium Chloride | Potassium Chloride | 41 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 41 | suppressed |
| Irbesartan | Irbesartan | 37 | suppressed |
| Sucralfate | Sucralfate | 37 | suppressed |
| Levetiracetam | Levetiracetam | 36 | suppressed |
| Memantine Hcl | Memantine Hcl | 36 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 35 | suppressed |
| Pregabalin | Pregabalin | 35 | suppressed |
| Methylprednisolone | Methylprednisolone | 34 | 31 |
| Colesevelam Hcl | Colesevelam Hcl | 33 | suppressed |
| Aripiprazole | Aripiprazole | 32 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 32 | suppressed |
| Prednisone | Prednisone | 32 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 31 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 30 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 30 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 29 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | suppressed |
| Chlorthalidone | Chlorthalidone | 28 | suppressed |
| Clonazepam | Clonazepam | 28 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 28 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 26 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 25 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 25 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Lansoprazole | Lansoprazole | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 12 |
| Arformoterol Tartrate | Arformoterol Tartrate | 24 | suppressed |
| Dutasteride-Tamsulosin | Dutasteride/Tamsulosin Hcl | 24 | suppressed |
| Famotidine | Famotidine | 24 | suppressed |
| Nystatin | Nystatin | 24 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 24 | suppressed |
| Roflumilast | Roflumilast | 24 | suppressed |
| Allopurinol | Allopurinol | 23 | suppressed |
| Carbamazepine | Carbamazepine | 23 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 23 | suppressed |
| Mounjaro | Tirzepatide | 23 | suppressed |
| Vascepa | Icosapent Ethyl | 23 | suppressed |
| Alprazolam | Alprazolam | 22 | suppressed |
| Gemfibrozil | Gemfibrozil | 22 | suppressed |
| Nitroglycerin | Nitroglycerin | 22 | suppressed |
| Brilinta | Ticagrelor | 21 | suppressed |
| Estradiol | Estradiol | 21 | suppressed |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Lactulose | Lactulose | 21 | suppressed |
| Naproxen | Naproxen | 21 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 20 | suppressed |
| Digoxin | Digoxin | 20 | suppressed |
| Fentanyl | Fentanyl | 20 | suppressed |
| Levofloxacin | Levofloxacin | 20 | 19 |
| Lorazepam | Lorazepam | 20 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 19 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 18 | suppressed |
| Methotrexate | Methotrexate Sodium | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 18 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 17 | suppressed |
| Ozempic | Semaglutide | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 16 | suppressed |
| Azithromycin | Azithromycin | 15 | 13 |
| Bumetanide | Bumetanide | 15 | suppressed |
| Cilostazol | Cilostazol | 15 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 13 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | 13 |
| Fluconazole | Fluconazole | 13 | 11 |
| Methadone Hcl | Methadone Hcl | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 12 | 12 |
| Pentoxifylline | Pentoxifylline | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Airsupra | Albuterol Sulfate/Budesonide | 11 | suppressed |
| Alcohol Swab | Alcohol Antiseptic Pads | 11 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Phenobarbital | Phenobarbital | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $165.85 · 9 records | Lilly USA, LLC | FANAPT, LEQVIO, MOUNJARO, REXULTI, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, VRAYLAR, XIFAXAN | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error